Lung cancer is the fifth most common cancer in Australia and accounts for 9% of all cancers. It was estimated that there would be 3,258 new cases of lung cancer diagnosed in Australia in 2020. The risk of being diagnosed with lung cancer in Australia by age 85 is 1 in 13 for men and 1 in 21 for women. The chance of surviving lung cancer for at least five years is 19%. There are two types of lung cancers namely, Non-Small Cell Lung Cancer (NSCLS), & Small Cell Lung Cancer (SCLC). Comparatively Non-small cell lung cancer is the most common type of lung cancer, accounting for around 85% of cases. The rising prevalence rate of lung cancer is a major driver of the lung cancer market. This is mainly because an increase in prevalence and incidence rate of lung cancer cases propels the need for drugs that enable efficient and fast treatment of the disease. Increasing funding in the field of research and development of new drugs, increasing pollution due to rapid industrialization, and a rise in the number of smokers are some of the reasons for the increasing prevalence of lung cancer. Hence all these factors have been driving the growth of the market. In 2018 Lung Foundation Australia pledged $ 450,000 in research and development. The latest data from the National Drug Strategy Household Survey (NDSHS) estimated that 11.6% of adults smoked daily in 2019. In 2017-18, net overseas migration was 236,700 and the natural increase was 153,800. In total, Australia’s population grew by 390,500, or 1.6 percent. Visit https://insights10.com/ for more healthcare industry insights. Connect with us at info@insights10.com

1. 1
Australia Lung
Cancer Drugs
Market
Lung Cancer Drugs Market Size and Share, Segmented
by- Type, by Treatment, by End User, by Route of
Administration, by Distribution Channel and Forecast
2020 till 2028
Sample Report

2. 2
2 Confidential
Table of Content
1. Australia Lung Cancer Drugs Market Overview……………………………………..………………………………………….………………………………....…07
a. Market size and forecast
2. Market Growth Drivers & Restraints………………………………………………………………………...……………..............................................................09
a. Market Growth Drivers
i. Rising Prevalence Rate of Lung Cancer
ii. Rapid Industrialization and Increase in Pollution
iii.Increasing funding in the field of research and development
b. Market Restraints
i. Efficacy and Cure Rates are Low with Increased Side Effects of Ongoing Therapies
ii. High Cost of Treatment
iii. Regulatory Changes Pose Difficulties
3. Australia Lung Cancer Drugs Market Segmentation……………………………………….………………………………………………………………………..16
a. Drugs By Type
i. Small Cell Lung Cancer (SCLC)
ii. Non-Small Cell Lung Cancer (NSCLC)

3. 3
3 Confidential
Table of Content
b. By Treatment
i. Chemotherapy
ii. Radiotherapy
iii. Immunotherapy
iv. Other Drugs
c. By End User
i. Hospitals & Clinics
ii. Cancer Research Centers
iii. Laboratories
d. By Route of Administration
i. Oral
ii. Parentrals
iii. Others
e. By Distribution Channel
i. Hospital Pharmacies
ii. Retail Pharmacies
iii. Online Pharmacies
4. Australia Lung Cancer Drugs Market Share By Application………………...………………………………………………………..…………………….....…23
a. Market Share by Application
b. Key Findings

4. 4
4 Confidential
Table of Content
5. Competitive Landscape……………………………………………………………………………………………………………………………………………….........….25
a. Top companies in Australia Lung Cancer Drugs Market
b. Insights & Forecast (Company Market Position Analysis
6. Key Company Profiles…………………………………………………………………………………..………………………………………………………..……............27
a. Sanofi Company overview, Product & Services, Strategies & Financials
b. Bristol-Myers Squibb Company, Product & Services, Strategies & Financials
c. Pfizer Company, Product & Services, Strategies & Financials
d. Hoffmann-La Roche Company, Product & Services, Strategies & Financials
e. AstraZeneca Company, Product & Services, Strategies & Financials
f. Boehringer Ingelheim Company, Product & Services, Strategies & Financials
g. Eli Lilly and Company, Product & Services, Strategies & Financials
h. GlaxoSmithKline Company, Product & Services, Strategies & Financials
7. R&D initiatives by major companies……………………………………………………………………………………….……………………………………….………..45
a. R&D Expenditure By Major Companies
b. R&D Initiatives- Insights
8. Access and Reimbursement Scenario………………………………………………………………………………………………..……………………….…..…………48
a. Region specific reimbursement scenario
b. Key market consideration in Lung Cancer by Region

5. 5
5 Confidential
Table of Content
9. Factors Driving Future Growth……………………………………………………………………………………………………………………………...……...…..........50
a. Future Opportunities
10. Conclusion………………………………………………………………………………………………………………………………………………………..……………..52

6. 6
Australia Lung Cancer Drugs Market Overview

7. 7
7 Confidential
Australia Lung Cancer Drugs - Market Size & Forecast Overview
Key Analysis
Australia Lung Cancer Drugs Market Size ($Bn) (2020-2028)
 The Australia Lung Cancer Drug market size stood at
around USD 0.59 Billion in 2019 and is projected to reach
USD xx billion by 2028
 In Australia, Lung Cancer is the leading cause of cancer
death, and has the lowest five-year relative survival rate
(17%) when compared to the other top five most commonly
diagnosed cancers
 The rising prevalence of lung cancer, excessive tobacco
usage, active participation in passive smoking, and
exposure to high levels of pollution have all contributed to
the Lung Cancer market's robust expansion in Australia
 We expect the market to continue to grow at a rate of over
xx% annually, driven primarily by the release of key
treatment guidance, new drug launches in the Australia and
increasing drug availability in other regions
0.59

8. 8
Australia Lung Cancer Drugs Market: Growth
Drivers and Growth Restraints

9. 9
9 Confidential
Market Growth Drivers And Restraints
Rising Prevalence
Rate of Lung Cancer
Regulatory Changes Pose
Difficulties
Efficacy and Cure Rates are Low
with Increased Side Effects of
Ongoing Therapies
Impact
Impact
Market
Drivers
Market
Restraints
Rapid Industrialisation
and Increase in
Pollution
High Cost of Treatment
Increasing funding in
the field of research
and development

10. 10
10 Confidential
Market Growth Drivers
1. RISING PREVALENCE RATE OF LUNG CANCER
In 2016, lung cancer was Australia's fifth most often diagnosed malignancy. In 2020, there were expected to be 13,258
new cases of lung cancer diagnosed and 8,641 deaths. In Australia, 13,258 new cases of lung cancer were
roughly detected in 2020. (7,238 males and 6,020 females)
Lung cancer is Australia's one of the most frequent cancer, accounting for 9% of all malignancies. In 2021, it is expected
that 13,810 new cases of lung cancer will be diagnosed in Australia. By the age of 90, one in every 18 Australians will be
diagnosed with lung cancer
Lung cancer patients have a 19% chance of surviving for at least five years. Hence, the rise in the number of cases with
lung cancer is one major growth driver as with increased cases a huge amount of medicines are also required for the
treatment

11. 11
11 Confidential
Market Growth Drivers (continued)
2. RAPID INDUSTRIALIZATION AND INCREASE IN POLLUTION
Air pollution has long been connected to a number of illnesses. Some substances have previously been classified as
carcinogenic, such as diesel exhaust. However, this is the first time that air pollution has been recognised as a carcinogen
in its totality
With the increase in pollution (to some extend due to industrialization) there will be increase in the incidences of Lung
Cancer which ultimately requires increased number of drugs/therapies for its treatment
The International Agency for Research on Cancer (IARC) looked at thousands of studies on air pollution and discovered
that it raised the incidence of lung cancer and bladder cancer. The risk may be comparable to breathing second-hand
tobacco smoke, depending on the level of exposure

12. 12
12 Confidential
Market Growth Drivers (continued)
3. Increasing Funding in Research and Development
Australia has been in leading position for research and development. In 2018 Lung Foundation Australia pledged $ 450,000 in research and
development
Sample
Australian market has presence of world’s top companies with heavy R&D spend. Australian government support to
develop ecosystem that is favourable to research and development for pharma and life science industry

13. 13
13 Confidential
Market Restraints
1. EFFICACY AND CURE RATES ARE LOW WITH INCREASED SIDE EFFECTS OF ONGOING THERAPIES
Chemotherapy (chemo) is an anti-cancer treatment in which anti-cancer medications are injected into a vein or eaten
orally. These medications travel through the bloodstream and reach nearly every part of the body but have various side
effects as well which are clearly visible
Specific side effects are possible with some medications. Drugs like Cisplatin, Vinorelbine, Docetaxel, and Paclitaxel, for
example, might induce nerve injury (peripheral neuropathy). This might cause symptoms such as discomfort, burning or
tingling feelings, cold sensitivity, or weakness (especially in the hands and feet)
The number of lung cancer deaths grew from 5,288 in 1982 (4,227 males and 1,061 females) to 8,586 in 2018. During the
same time span, the age-standardised mortality rate fell from 42 deaths per 100,000 people in 1982 (79 for men and 15 for
women) to 28 deaths per 100,000 in 2018

14. 14
14 Confidential
Market Restraints (continued)
2. HIGH COST OF TREATMENT
Despite the fact that the number of therapies has expanded, their cost has also increased. Drugs with recent
advancements are expensive, and not everyone can afford them, leaving people feeling helpless.
This increase in treatment cost for the Lung Cancer has somehow resulted in the increment of malpractices in health
insurances for the same
From one year before diagnosis to three years after diagnosis, excess costs averaged $51,900 per instance. Cases
diagnosed in Australia at 45–59 years of age ($67,700) or 60–69 years of age ($63,500) had higher costs, while cases
detected at 80 years of age ($29,500) and those with undefined histology ($31,700) or unknown stage ($36,500) had lower
prices

15. 15
15 Confidential
Market Restraints (continued)
15
3. REGULATORY CHANGES POSE DIFFICULTIES
Regulatory changes are anticipated to raise expenses associated with new product development and client service
offerings. The General Data Protection Regulation (GDPR), changes to drug approval procedures, and other regulatory
adjustments are all part of these shifts
Fortune's Global 500 companies spends roughly $7.8 billion in order to ensure they are compliant with the General Data
Protection Regulation
The possible loss of revenue owing to product delays and higher costs incurred as a result of tight approval processes
puts a pressure on new product development investments, hurting the pharmaceutical companies market's growth

16. 16
Australia Lung Cancer Drugs Market : Market
Segmentation

17. 17
17 Confidential
Australia Lung Cancer Drugs Market Segmentation
By Type By Treatment By End User
By Route of
Administration
Australia Lung Cancer Drugs Market Segmentation
Chemotherapy
Radiotherapy
Immunotherapy
Hospitals & Clinics
Cancer Research
Centers
Laboratories
Oral
Parentrals
Others
Small Cell Lung Cancer
(SCLC)
Non-Small Cell Lung
Cancer (NSCLC)
Other Drugs
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

18. 18
18 Confidential
Type 2020 2021 2023 2025 2028 CAGR
Small Cell
Lung Cancer
Non-Small
Cell Lung
Cancer
Market Segmentation: By Type
Revenue in USD Mn, by Type, Australia, 2020-2028
Lung Cancer Drug Market Share by Type 2020
 Small cell lung cancer and non–small cell lung cancer are the two main forms of lung cancer, which are named after the size of
the cancer cells observed under a microscope.
 Non–small cell lung cancer accounts for 85–90% of all lung cancers in Australia
 In Australia, about 7500 patients die from lung cancer each year and the median survival for those with metastatic non-small cell
lung cancer (NSCLC) is 4–5 months
Key Insights
SCLC
NSCLC

19. 19
19 Confidential
Market Segmentation: By Treatment
Key Summary
Lung Cancer Drug Market Share by Treatment 2020
 75% of cases had a record of drug cancer-related
treatment: 22% received surgery, 46% chemotherapy
and 48% radiotherapy
 Immunotherapy is a type of treatment that uses drugs
to increase the immune system's ability to fight
cancer cells. Some types of non–small cell lung
cancer can be treated with immunotherapy
 70% of cases in age 45–59 receives chemotherapy
where as only 18% of cases received this treatment
in age group of above 80 years
Chemotherapy
Radiotherapy
Immunotherapy
Other Drugs

20. 20
20 Confidential
Market Segmentation: By End User
Lung Cancer Drugs Market Share by End User 2020
 Lung Cancer Drug Market will be driven with hospitals
and clinics accounting for the largest segment
 Recent policy changes around Australian
Reimbursement for Lung cancer allow patients to
seek treatment in hospital and can extend the claim
under pharmacy benefit scheme
Key Summary
Hospitals & Clinics
Cancer Research
Centers
Laboratories

21. 21
21 Confidential
SAMPLE
By method of administration, the parental segment of the
cancer medications market accounted for 53.5 %of the
overall oncology market
Key Highlights
Market Segmentation: By Route of Administration
Lung Cancer Drugs Market Share by Route of
Administration 2020
Oral
Parentrals
Others

22. 22
22 Confidential
Hospital pharmacies account the major share in this segment
withowing to the strong presence of hospital pharmacies,
increase in the number of hospitalized Lung cancer patients,
and convenience offered by hospital pharmacies.
By Distribution channel, Lung cancer drug market in Australia
is segmented into hospital pharmacies, retail pharmacies and
online pharmacies
Key Highlights
Market Segmentation: By Distribution Channel
Lung Cancer Drugs Market Share by Route of
Administration 2020
Hospital
Pharmacies
Retail
Pharmacies
Online
Pharmacies
SAMPLE

23. 23
Australia Lung Cancer Drugs : Market Share By
Application

24. 24
24 Confidential
Major Market Share By Application
Lung Cancer Drugs Market in Australia
 Lung Cancer drugs market has been increasing in Australia
as noticed over past few years due to the increase the in the
cases that have been emerging majorly in form of lifestyle
change disease
 Currently the respective companies are working on the
modern treatment method both in terms of drug products and
technology. Companies are running various drug molecule in
the pipeline which can be used as soon as approved
Key Findings
Combined Therapy
PD-1/PD-L1 inhibitors
ALK Inhibitors
EGFR Inhibitor

25. 25
Australia Lung Cancer Drugs Market: Key Players
/ Competitive Landscape

26. 26
26 Confidential
Competitive Landscape: Key Players Revenue (Current and Forecasted)
Major Market Revenue of Lung Cancer Drugs Companies in Australia ($Bn)
2020 2021 2022 2023 2024 2025 2026 2027 2028
Sanofi xx - - - - - - - -
Bristol-Myers Squibb xx - - - - - - - -
Pfizer xx - - - - - - - -
Hoffmann-La Roche xx - - - - - - - -
AstraZeneca xx - - - - - - - -
Boehringer Ingelheim xx - - - - - - - -
Eli Lilly and
Company
xx - - - - - - - -
Glaxo Smith Kline xx - - - - - - - -

27. 27
27 Confidential
Competitive Landscape: Key Players Market Share
Lung Cancer Drugs Major Market Share
• In Australia Major oncology pharma players have their
presence. Sanofi and Boehringer Ingelheim are working on
developing drugs of lung cancer treatments, including Ofev
and SAR442720.
 The rising incidences of lung cancer made the companies
to develop more and better efficiency products for these
diseases
Key Insights
Sanofi
Bristol-Myers Squibb
Roche
Pfizer
AstraZeneca
Boehringer Ingelheim
Eli Lilly
GSK

28. 28
Key Company Profiles

29. 29
29 Confidential
Sanofi
Company Name: Sanofi
Year of Establishment: 1973
Headquarter: Paris, France
Revenue: $42.69 Billion
Website: https://www.sanofi.com/
Company Profile
 Sanofi is a multinational pharmaceutical business based in
Paris, France, and the world's fifth-largest by prescription sales
as of 2013.
 Sanofi is a worldwide healthcare leader with a focus on
producing solutions that address people's health needs
 Sanofi has more than 100,000 employees globally,
representing 145 different nationalities, working to provide
healthcare solutions in more than 170 countries
 Content

30. 30
30 Confidential
Sanofi
Revenues ($Bn), 2020-2028 Breakdown of net revenue (%) by segment, 2020
Analysis
 The company registered 4.2% increment in its annual revenue from 2019 to 2020
 Oncology group holds the dominant market position and have shown a increase of 54% for the drug called “Dupixent”
 The company have spend around 2 Billion Euros for the R&D sector
42.69
Oncology
Cardiology
Diabetes
Others

31. 31
31 Confidential
Bristol-Myers Squibb
Company Name: Bristol-Myers Squibb
Year of Establishment: 1887
Headquarter: New York, US
Revenue: $42.5 Billion
Website: https://www.bms.com/
Company Profile
Sample

32. 32
32 Confidential
Bristol-Myers Squibb
Revenues ($Bn), 2020-2028 Breakdown of net revenue (%) by segment, 2020
Analysis
Sample

33. 33
33 Confidential
Pfizer
Company Name: Pfizer
Year of Establishment: 1849
Headquarter: New York, US
Revenue: $41.91 Billion
Website: https://www.pfizer.com/
Company Profile
Sample

34. 34
34 Confidential
Pfizer
Revenues ($Bn), 2020-2028 Breakdown of net revenue (%) by segment, 2020
Analysis
Sample

35. 35
35 Confidential
Hoffmann-La Roche
Company Name: Hoffmann-La Roche
Year of Establishment: 1896
Headquarter: Basel, Switzerland
Revenue: $31.8 Billion
Website: https://www.roche.com/
Company Profile
Sample

36. 36
36 Confidential
Hoffmann-La Roche
Revenues ($Bn), 2020-2028 Breakdown of net revenue (%) by segment, 2020
Analysis
Sample

37. 37
37 Confidential
AstraZeneca
Company Name: AstraZeneca
Year of Establishment: 1999
Headquarter: Cambridge, UK
Revenue: $26.6 Billion
Website: https://www.astrazeneca.com/
Company Profile
Sample

38. 38
38 Confidential
AstraZeneca
Revenues ($Bn), 2020-2028 Breakdown of net revenue (%) by segment, 2020
Analysis
Sample

39. 39
39 Confidential
Boehringer Ingelheim
Company Name: Boehringer Ingelheim
Year of Establishment: 1885
Headquarter: Ingelheim, Germany
Revenue: $23.19 Billion
Website: https://www.boehringer-ingelheim.com/
Company Profile
Sample

40. 40
40 Confidential
Boehringer Ingelheim
Revenues ($Bn), 2020-2028 Breakdown of net revenue (%) by segment, 2020
Analysis
Sample

41. 41
41 Confidential
Eli Lilly and Company
Company Name: Eli Lilly and Company
Year of Establishment: 1876
Headquarter: Indiana, US
Revenue: $22.32 Billion
Website: https://www.lilly.com/
Company Profile
Sample

42. 42
42 Confidential
Eli Lilly and Company
Revenues ($Bn), 2020-2028 Breakdown of net revenue (%) by segment, 2020
Analysis
Sample

43. 43
43 Confidential
GlaxoSmithKline
Company Name: GlaxoSmithKline
Year of Establishment: 2000
Headquarter: London, UK
Revenue: 8.2 Billion GBP
Website: https://www.gsk.com/en-gb/home/
Company Profile
Sample

44. 44
44 Confidential
GlaxoSmithKline
Revenues ($Bn), 2020-2028 Breakdown of net revenue (%) by segment, 2020
Analysis
Sample

45. 45
R&D Initiatives By Major Companies

46. 46
46 Confidential
R&D Expenditure By Major Companies
Sanofi and Regeneron announced that the two companies had
more than doubled their investment in cemiplimab, to $1.6
billion. This will fund a broad clinical program in a range of
cancers including non-small cell lung cancer
Key Insights R&D Expenditure of Major Companies ($Bn), 2020
Sample
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
AstraZeneca
Boehringer Ingelheim
GSK
Sample

47. 47
47 Confidential
R&D Initiatives In Lung Cancer Drugs
 ALK inhibitors are a type of targeted treatment medication. They are looking for a cancer-causing mutation in the ALK gene. These
medications are still being improved for the 5% of lung cancer patients who have an ALK gene mutation
 Some cancer cells have been discovered to express the proteins PD-L1 and PD-L2 on their cell membranes, successfully shielding
them from the immune system. Recent immunotherapies disrupt the PD-L1/2 and PD-1 receptor pathways, allowing cancer cells to
be detected and killed by Cytotoxic T cells, removing the brakes on the immune system
 Sanofi started phase 1 clinical trial in 2018 for SAR442720, an SHP2 inhibitor for the treatment of advanced non-small cell lung
cancer as well as Phase I/II study with isatuximab in combination with cemiplimab in patients with advanced malignancies (prostate
and non-small cell lung cancer)
 Sample Content

48. 48
Access And Reimbursement Scenario

49. 49
49 Confidential
Access and reimbursement scenario: Australia
 For each 12-month period, Indigenous Australians with cancer
spent less than half of what non-Indigenous Australians spent
(0–12 months: mean $401 Indigenous vs. $1074 non-
Indigenous; 13–24 months: mean $200 vs. $484; and 25–36
months: mean $181 vs. $441)
 In 2019–20, total health expenditures is expected to be $81.8
billion, accounting for 16.3% of the Australian government's
total spending
 Lung cancer alone is predicted to cost $297.3 million in direct
(treatment, transport, and out-of-hospital costs) and indirect
costs for new patients diagnosed in 2018 (absenteeism)
Key Market Access Considerations
General reimbursement Scenario
Sample

50. 50
Future Development Growth

51. 51
51 Confidential
Future Opportunities
Surgery, radiation, chemotherapy, targeted therapy, immunotherapy, and combinations of these treatments are all options for
lung cancer treatment. Targeted therapy is the most popular amongst Australians, so this treatment segment should be
developed more
The majority of lung cancer cases in Australia are non-small cell lung cancer (NSCLC) and there is no treatment available to give
a permanent cure from this diseased condition. Hence, the Researchers can dig deep into this as it have a lot of potential to
grow
The future of Lung Cancer Drugs health aims to create a patient centric healthcare system where the life expectancy of the
patient can be prolonged and the detection of cancer can be done in early stages so that the treatment can be started at the
earliest
Sample Content
Sample Content
Sample Content

52. 52
Conclusion

53. 53
53 Confidential
Conclusion
1
2
3
5
4
Strong Demand
As there are increased number of
cases witnessed in Australia due
to various reasons, the amount of
drugs needed to provide the
proper treatment will increase as
well. Hence, the demand for the
Lung Cancer drugs have been
increased
Emerging Initiative
One of the main initiatives to
ensure the valuable treatment for
the patients is to get the early
detection. Also the government
have been working to reduce the
number of smokers, which is one
of the cause for lung cancer
Availability of Technology
The recent advanced treatment in
the field is of Targeted Therapy
and Immunotherapy. Along with
this in randomised controlled
studies, screening with low-dose
computed tomography scans has
been shown to be useful for
discovering early curable disease,
reducing death by 20%
Stakeholder Coverage
The top notch pharmaceutical
companies have the major share in
the market as this field requires a
lot of research & development
which the small scale industries are
not able to afford
Advancement in healthcare delivery
These top companies have many
products running in their pipeline which
can be used once completed the trials